U.S. flag

An official website of the United States government

NM_024675.4(PALB2):c.1317del (p.Phe440fs) AND Hereditary breast ovarian cancer syndrome

Germline classification:
Pathogenic (2 submissions)
Last evaluated:
Apr 1, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001193417.4

Allele description [Variation Report for NM_024675.4(PALB2):c.1317del (p.Phe440fs)]

NM_024675.4(PALB2):c.1317del (p.Phe440fs)

Gene:
PALB2:partner and localizer of BRCA2 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
16p12.2
Genomic location:
Preferred name:
NM_024675.4(PALB2):c.1317del (p.Phe440fs)
HGVS:
  • NC_000016.10:g.23635231del
  • NG_007406.1:g.11129del
  • NM_024675.4:c.1317delMANE SELECT
  • NP_078951.2:p.Phe440fs
  • LRG_308:g.11129del
  • NC_000016.9:g.23646550del
  • NC_000016.9:g.23646552del
  • NM_024675.3:c.1317delG
  • NM_024675.4:c.1317del
  • p.F440Lfs*12
  • p.F440LfsX12
  • p.Phe440Leufs*12
Links:
dbSNP: rs515726067
NCBI 1000 Genomes Browser:
rs515726067
Molecular consequence:
  • NM_024675.4:c.1317del - frameshift variant - [Sequence Ontology: SO:0001589]
Observations:
1

Condition(s)

Name:
Hereditary breast ovarian cancer syndrome
Synonyms:
Hereditary breast and ovarian cancer syndrome; Hereditary breast and ovarian cancer; Hereditary breast and ovarian cancer syndrome (HBOC); See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0003582; MeSH: D061325; MedGen: C0677776; Orphanet: 145

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001362218Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(Apr 1, 2021)
germlineclinical testing

PubMed (6)
[See all records that cite these PMIDs]

Citation Link,

SCV002588989BRCAlab, Lund University
no assertion criteria provided
Pathogenic
(Aug 26, 2022)
germlineclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot provided1not providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.

LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, Chen E, Gau CL, Palmaer E, Shoaepour K, Shah D, Speare V, Gandomi S, Chao E.

Genet Med. 2014 Nov;16(11):830-7. doi: 10.1038/gim.2014.40. Epub 2014 Apr 24.

PubMed [citation]
PMID:
24763289
PMCID:
PMC4225457

Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients.

Sokolenko AP, Preobrazhenskaya EV, Aleksakhina SN, Iyevleva AG, Mitiushkina NV, Zaitseva OA, Yatsuk OS, Tiurin VI, Strelkova TN, Togo AV, Imyanitov EN.

Cancer Lett. 2015 Apr 10;359(2):259-61. doi: 10.1016/j.canlet.2015.01.022. Epub 2015 Jan 22.

PubMed [citation]
PMID:
25619955
See all PubMed Citations (6)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001362218.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (6)

Description

Variant summary: PALB2 c.1317delG (p.Phe440LeufsX12) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 249846 control chromosomes. c.1317delG has been reported in the literature in several individuals and in at least one family affected with Hereditary Breast and Ovarian Cancer (e.g. Balia 2010, Tung 2015, Sokolenko 2015, Susswein 2015, Sun 2017). These data indicate that the variant is very likely to be associated with disease. One study noted that the there was a differential expression of the WT and the mutated mRNA, presumably due to nonsense mediated decay (NMD), though no experimental data was provided (Balia 2010). Seven clinical diagnostic laboratories and one database (LOVD) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Some submitters cite overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From BRCAlab, Lund University, SCV002588989.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot provided1not provided

Last Updated: Sep 8, 2024